Biagon Inc. is a biotechnology company focused on developing novel therapeutic candidates. The company maintains a pipeline of preclinical and clinical stage assets targeting unmet medical needs. They advance their proprietary drug discovery programs through focused research and development efforts.
Funding
Funding not disclosed
Founders
Product
Problem
G protein-coupled receptors (GPCRs) are a major class of drug targets, but their complex signaling pathways and conformational changes make it difficult to predict drug efficacy and optimize therapeutic outcomes. Many GPCRs are considered "undruggable" due to challenges in discovering novel chemical matter and understanding their signaling complexity.
Solution
Biagon is developing machine learning solutions that model the conformational space of GPCRs to predict signaling efficacy across various pathways. Their platform, Bronzeville, operates on the principle that the equilibrium of the ligand-induced conformational ensemble is linearly proportional to the activation of cellular signals. By combining biophysics and machine learning, Biagon aims to provide drug developers with powerful tools to address challenges associated with targeting GPCRs, including predicting and untangling their signaling complexity. This approach enables a deeper understanding of the molecular mechanisms of receptor activation and inhibition, leading to optimized therapeutic strategies.
Target Audience
The primary customers are drug developers and researchers targeting GPCRs for a wide range of indications.
Features
- Machine learning models that predict GPCR signaling efficacy.
- Biophysics-based approach to model the conformational space of GPCRs.
- Bronzeville platform that links ligand-induced conformational changes to cellular signal activation.